CA2494764C - Treatment of melanoma by reduction in clusterin levels - Google Patents
Treatment of melanoma by reduction in clusterin levels Download PDFInfo
- Publication number
- CA2494764C CA2494764C CA2494764A CA2494764A CA2494764C CA 2494764 C CA2494764 C CA 2494764C CA 2494764 A CA2494764 A CA 2494764A CA 2494764 A CA2494764 A CA 2494764A CA 2494764 C CA2494764 C CA 2494764C
- Authority
- CA
- Canada
- Prior art keywords
- clusterin
- oligodeoxynucleotide
- melanoma
- antisense
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000003780 Clusterin Human genes 0.000 title claims abstract description 77
- 108090000197 Clusterin Proteins 0.000 title claims abstract description 77
- 201000001441 melanoma Diseases 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 230000009467 reduction Effects 0.000 title abstract description 9
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 38
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 6
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 32
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
- 230000014621 translational initiation Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 108091007065 BIRCs Proteins 0.000 abstract description 3
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 40
- 108091030071 RNAI Proteins 0.000 description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 35
- 101000942697 Homo sapiens Clusterin Proteins 0.000 description 26
- 102000056179 human CLU Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000030833 cell death Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical group CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical class CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001876 chaperonelike Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40519302P | 2002-08-21 | 2002-08-21 | |
| US60/405,193 | 2002-08-21 | ||
| US40815202P | 2002-09-03 | 2002-09-03 | |
| US60/408,152 | 2002-09-03 | ||
| US31974802P | 2002-12-02 | 2002-12-02 | |
| US60/319,748 | 2002-12-02 | ||
| US47238703P | 2003-05-20 | 2003-05-20 | |
| US60/472,387 | 2003-05-20 | ||
| PCT/CA2003/001276 WO2004018675A1 (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2494764A1 CA2494764A1 (en) | 2004-03-04 |
| CA2494764C true CA2494764C (en) | 2013-04-23 |
Family
ID=31950766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2494764A Expired - Fee Related CA2494764C (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7285541B2 (https=) |
| EP (1) | EP1530636B1 (https=) |
| JP (1) | JP4620585B2 (https=) |
| KR (1) | KR101052289B1 (https=) |
| AT (1) | ATE478142T1 (https=) |
| AU (1) | AU2003258425B2 (https=) |
| CA (1) | CA2494764C (https=) |
| CY (1) | CY1110936T1 (https=) |
| DE (1) | DE60333839D1 (https=) |
| DK (1) | DK1530636T3 (https=) |
| IL (1) | IL166657A (https=) |
| NO (1) | NO333254B1 (https=) |
| NZ (1) | NZ538288A (https=) |
| PT (1) | PT1530636E (https=) |
| SI (1) | SI1530636T1 (https=) |
| WO (1) | WO2004018675A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| SI1530636T1 (sl) | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| KR101238701B1 (ko) | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| BRPI0508970A (pt) * | 2004-03-19 | 2007-08-21 | Penn State Res Found | método combinatórios e composições para o tratamento de melanoma |
| US8710020B2 (en) | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
| CA2584646C (en) * | 2004-11-23 | 2015-11-03 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| KR20080065617A (ko) * | 2005-09-19 | 2008-07-14 | 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 | 글루코코티코이드 수용체 발현의 조절 |
| AU2008293138A1 (en) * | 2007-08-28 | 2009-03-05 | Auckland Uniservices Limited | Cell marker of melanocyte cell lineage and uses thereof |
| EA034462B1 (ru) | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| SG192957A1 (en) | 2011-03-15 | 2013-09-30 | Univ British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| WO2014159775A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Pharmaceutical Industries Ltd. | Anti-clusterin monotherapy for cancer treatment |
| US20230243852A1 (en) * | 2022-01-26 | 2023-08-03 | Idexx Laboratories, Inc. | Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| JP4785252B2 (ja) * | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CA2393646A1 (en) | 1999-12-21 | 2001-06-28 | Yale University | Survivin promotion of angiogenesis |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2003062421A1 (en) * | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| KR101238701B1 (ko) * | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| SI1530636T1 (sl) | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US8061408B2 (en) | 2009-10-13 | 2011-11-22 | Varel Europe S.A.S. | Casting method for matrix drill bits and reamers |
-
2003
- 2003-08-21 SI SI200331891T patent/SI1530636T1/sl unknown
- 2003-08-21 DE DE60333839T patent/DE60333839D1/de not_active Expired - Lifetime
- 2003-08-21 JP JP2005501197A patent/JP4620585B2/ja not_active Expired - Fee Related
- 2003-08-21 NZ NZ538288A patent/NZ538288A/en not_active IP Right Cessation
- 2003-08-21 WO PCT/CA2003/001276 patent/WO2004018675A1/en not_active Ceased
- 2003-08-21 CA CA2494764A patent/CA2494764C/en not_active Expired - Fee Related
- 2003-08-21 AU AU2003258425A patent/AU2003258425B2/en not_active Ceased
- 2003-08-21 KR KR1020057002964A patent/KR101052289B1/ko not_active Expired - Fee Related
- 2003-08-21 US US10/646,391 patent/US7285541B2/en not_active Expired - Fee Related
- 2003-08-21 DK DK03792074.1T patent/DK1530636T3/da active
- 2003-08-21 PT PT03792074T patent/PT1530636E/pt unknown
- 2003-08-21 EP EP03792074A patent/EP1530636B1/en not_active Expired - Lifetime
- 2003-08-21 AT AT03792074T patent/ATE478142T1/de active
-
2005
- 2005-02-02 IL IL166657A patent/IL166657A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051426A patent/NO333254B1/no not_active IP Right Cessation
-
2010
- 2010-11-19 CY CY20101101046T patent/CY1110936T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050058425A (ko) | 2005-06-16 |
| PT1530636E (pt) | 2010-11-17 |
| ATE478142T1 (de) | 2010-09-15 |
| SI1530636T1 (sl) | 2010-12-31 |
| EP1530636A1 (en) | 2005-05-18 |
| NO333254B1 (no) | 2013-04-22 |
| WO2004018675A1 (en) | 2004-03-04 |
| AU2003258425B2 (en) | 2008-02-14 |
| CY1110936T1 (el) | 2015-06-10 |
| DE60333839D1 (de) | 2010-09-30 |
| IL166657A0 (en) | 2006-01-15 |
| CA2494764A1 (en) | 2004-03-04 |
| NO20051426L (no) | 2005-05-12 |
| JP2006502243A (ja) | 2006-01-19 |
| US7285541B2 (en) | 2007-10-23 |
| DK1530636T3 (da) | 2010-11-29 |
| JP4620585B2 (ja) | 2011-01-26 |
| EP1530636B1 (en) | 2010-08-18 |
| KR101052289B1 (ko) | 2011-07-27 |
| AU2003258425A1 (en) | 2004-03-11 |
| US20040082534A1 (en) | 2004-04-29 |
| IL166657A (en) | 2010-05-31 |
| NZ538288A (en) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2494764C (en) | Treatment of melanoma by reduction in clusterin levels | |
| EP1163254B1 (en) | Trpm-2 antisense therapy | |
| US9085769B2 (en) | Compositions and methods for treatment of prostate and other cancers | |
| ES2350978T3 (es) | Tratamiento del melanoma mediante la reducción de los niveles de clusterina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180821 |